July 28, 2020 9:26 AM EDT

Send to a Friend

Oppenheimer analyst Jay Olson raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $105.00 (from $89.00) while maintaining a ...

This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Source link